http://www.wsj.com/articles/SB10001424127887323401904578158803776...

http://www.wsj.com/articles/SB10001424127887323401904578158803776251238

Doesn't look like Aquadex was a core product for Baxter when they purchased Gambo.

http://www.medscape.com/viewarticle/852427#vp_2

Looks like Baxter lost interest in a non core small bickers asset.
So like SSH's trial, slow but not untypical enrolment. Lots of ifs and buts. Nobodies really clear if the trial is demonstrating the difference between diruretics and aquadex or a systemicly incomplete and patchy understanding of HF.
Aquadex looks like a doubling up of the bet. Ssh has learnt a great deal about HF over the last few years. It's now claiming it can apply it successfully to two products.